Gentian Diagnostics AS serves the global market with sensitive diagnostic tests. Current and pipeline products contribute to improved diagnostics and cost reductions in treatment of kidneys, inflammation, cardiovascular diseases, cancer and viral infections.
On 14th December, 2016, Gentian Diagnostics AS was admitted to the Oslo Stock Exchange list ‘Merkur Market’ under the ticker GENT-ME.
Find more information about the Gentian Share on Oslo Børs.
Learn more about Gentian Diagnostics AS here.